BCI-Assisted SCS-EXS for Gait Optimization

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-23

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the safety and technical feasibility of a novel brain-machine interface (BCI)-assisted spinal cord stimulation (SCS) and exoskeleton (EXS) system in patients with spinal cord injury (SCI). The primary aim is to determine whether the BCI-SCS-EXS system can safely and effectively improve lower limb motor function and quality of life in individuals with chronic SCI.

Participant Population:

Adults aged 14-65 years (sex/gender not limited). Patients with chronic SCI (≥6 months post-injury) classified as ASIA A, B, or C.

Individuals with stable health status, MMSE ≥22, and secondary education or above.

Primary Questions:

1. Is the BCI-SCS-EXS system safe and technically feasible for SCI rehabilitation?
2. Does the system improve lower limb motor function and quality of life in SCI patients?

Interventions:

Participants will undergo the following procedures:

Phase I (Implantation):

BCI implantation: ECoG electrodes placed over the motor cortex to decode lower limb movement intent.

SCS electrode implantation: 5-6-5 paddle electrodes at T11-L2 for targeted spinal cord stimulation.

Phase II (System Calibration):

BCI-SCS synchronization: Calibration of decoded motor intent to trigger SCS parameters.

SCS-EXO synchronization: Integration of SCS pulses with exoskeleton-assisted gait training.

Phase III (Rehabilitation):

Daily BCI-SCS-EXS training sessions (60 minutes, 5 times/week for 1 year). Adaptive adjustments to stimulation parameters and exoskeleton support based on performance.

Remote monitoring of device performance and emergency intervention for technical issues.

Outcome Measures:

Primary: Safety (adverse events, device performance, synchronization metrics). Secondary: Efficacy (motor function, neurophysiological function, quality of life).

Ethics and Safety:

Informed consent will be obtained from all participants. Adverse events will be monitored and reported according to CTCAE 5.0 guidelines.

Participant confidentiality will be strictly maintained. This study will provide foundational evidence for the safety and feasibility of the BCI-SCS-EXO system, paving the way for future randomized controlled trials in SCI rehabilitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rehabilitation Combining Spatiotemporal Spinal Cord Stimulation and Real-time Triggering Exoskeleton After Spinal Cord Injury

NCT06881134

Spinal Cord Injury Neuromodulation Robot Assisted Gait Training

RECRUITING NA

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

NCT06976229

Spinal Cord Injury Safety Clinical Trials +4 more

RECRUITING PHASE1

Spine and Brain Stimulation for Movement Recovery After Cervical Spinal Cord Injury

NCT06867809

Spinal Cord Injury Spinal Cord Injury Cervical

RECRUITING NA

Development of an Exoskeleton for Patients' Mobility.

NCT06513390

Healthy

COMPLETED NA

Brain Computer Interface: Neuroprosthetic Control of a Motorized Exoskeleton

NCT02550522

Traumatic Tetraplegia with Cervical Cord Injury

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries (SCI) Spinal Cord Injury, Chronic Spinal Cord Injury Spinal Cord Injury Cervical Spinal Cord Injury Thoracic Spinal Cord Injury (Quadraplegia) Motor Impairment Motor Deficits Gait Training Gait Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BCI-SCS-EXO

Participants will undergo a BCI-SCS-EXS intervention, involving implatation of high-density ECoG electrodes, as well as SCS electrodes. The system will be calibrated to synchronize BCI-decoded motor intent with SCS parameters and integrate with the exoskeleton (EXS) to provide synchronized gait assistance. Safety and efficacy assessments will be conducted at 1, 2, 3, 6, and 12 months post-intervention.

Group Type EXPERIMENTAL

BCI-SCS-EXS

Intervention Type DEVICE

Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes:

1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent.
2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation.
3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance.
4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS.
5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention.

This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BCI-SCS-EXS

Participants will undergo a BCI-SCS-EXS intervention designed to enhance neurorehabilitation for spinal cord injury (SCI). The intervention includes:

1. BCI Implantation: High-density ECoG electrodes placed over the motor cortex to decode lower limb movement intent.
2. SCS Electrode Implantation: 5-6-5 paddle electrodes implanted at T11-L2 to deliver targeted spinal cord stimulation.
3. System Calibration: BCI-SCS synchronization to trigger stimulation parameters based on decoded motor intent. SCS-EXS integration to provide synchronized gait assistance.
4. Rehabilitation Training: Daily training sessions (60 minutes, 5 times/week for 1 year) combining BCI-SCS-EXS.
5. Follow-Up: Safety and efficacy assessments at 1, 2, 3, 6, and 12 months post-intervention.

This intervention aims to promote neuroplasticity and functional recovery through brain-controlled spinal activation and synchronized exoskeleton assistance.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 14-65 years, any gender.
* Clinical diagnosis of spinal cord injury (SCI) due to trauma, inflammation, tumor, vascular disease, or iatrogenic factors, confirmed by medical history, physical examination, and ancillary tests, resulting in lower limb motor dysfunction.
* SCI diagnosed ≥6 months prior, with ≥1 month of continuous conventional rehabilitation (e.g., physical therapy, acupuncture, hydrotherapy, ≥3 hours daily) without significant improvement in motor function in the past 2 months.
* ASIA Impairment Scale (AIS) grade A, B, or C based on the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).
* Good general health with a life expectancy ≥12 months.
* Mini-Mental State Examination (MMSE) score ≥22.
* Educational attainment of secondary school or above.
* Willingness to participate, provide informed consent, and comply with study follow-up.

Exclusion Criteria

* Presence of diseases other than spinal cord injury (SCI) that affect lower limb motor function, including brain diseases (e.g., brain tumor, stroke), lower limb vascular diseases (e.g., lower limb vascular occlusion), peripheral nerve diseases, or lower limb bone diseases (e.g., osteoarthritis, joint contracture).
* Requires continuous medical interventions (e.g., tracheal intubation, nasogastric feeding) to maintain critical physiological functions (e.g., heartbeat, respiration, swallowing).
* Congenital or acquired structural abnormalities of the lower limb bones or muscles.
* Presence of surgical contraindications (e.g., anesthesia-related adverse reactions, coagulation risks, or surgeon's determination of unsuitability for surgery).
* Presence of active implantable devices except for SCS or BCI devices (e.g., pacemakers, defibrillators, drug infusion pumps, cochlear implants, sacral nerve stimulators).
* Unable to receive implantable devices due to other disease treatments or investigations, or requires magnetic resonance imaging (MRI) during the device implantation period.
* MRI shows structural damage \>50% in motor function areas (precentral and postcentral gyri, ventromedial sensorimotor areas, mid temporal lobe, Broca's area, Wernicke's area, Geschwind's area), or DTI shows damage \>50% in the posterior limb of the internal capsule.
* Severe cardiovascular disease: Above level II myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥450 ms in men, ≥470 ms in women), level III-IV heart failure (NYHA classification), or echocardiography showing LVEF \<50%.
* Coagulation abnormalities (INR \>1.5 ULN, PT \>ULN +4 s, or APTT \>1.5 ULN), hemorrhagic tendency, or undergoing thrombolytic or anticoagulant therapy.
* Severe infections within 4 weeks before surgery (requiring IV antibiotics, antifungals, or antivirals) or lumbar soft tissue infections, or unexplained fever \>38.5℃ during screening or before surgery.
* HIV infection, acquired immunodeficiency syndrome (AIDS), active tuberculosis, active hepatitis B (HBV DNA ≥500 IU/ml), hepatitis C (positive HCV antibody and detectable HCV-RNA), or co-infection of hepatitis B and C.

Severe cerebrovascular events (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, or pulmonary embolism within 12 months before enrollment.

* Metastatic malignancies or untreated malignant tumors.
* Major surgery or severe traumatic injuries, fractures, or ulcers within 4 weeks before enrollment.
* Addictive habits such as drug abuse or alcoholism.
* History of psychotropic drug abuse that is not controllable or presence of mental disorders, including major psychiatric illnesses (e.g., depression \[BDI score \>20\], anxiety, obsessive-compulsive disorder, schizophrenia, autism, chronic sleep disorders, consciousness disorders).
* Pregnant, breastfeeding, planning to conceive, or women of childbearing potential without reliable contraception.
* Participation in other clinical trials within the past month.
* Cognitive impairments or poor compliance from subjects, family members, or caregivers, or inability to complete at least 12 months of follow-up and rehabilitation training.
* Other conditions that increase the risk of study participation or device use, as determined by the investigator.

Minimum Eligible Age

14 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No